Search Results
CLL14: venetoclax-obinutuzumab improves PFS and MRD in untreated, reduced fitness CLL
Venetoclax plus obinutuzumab improves PFS and MRD-negativity in patients with previously untreat...
CLL14 trial thoughts
Dr. Gerson on Venetoclax/Obinutuzumab Combination in CLL
Fixed-duration therapy with venetoclax-obinutuzumab in frontline CLL
Venetoclax plus obinutuzumab in CKT CLL: analysis from the CLL14 trial
Dr. Siddiqi on the CLL14 Trial Results in CLL
CLL14: Can we treat CLL without chemotherapy, venetoclax plus obinutuzumab
CLL14 trial: do certain patients benefit more from venetoclax plus obinutuzumab in CLL?
Comment on fixed-duration venetoclax plus obinutuzumab in patients with CLL and comorbidities
Venetoclax-Obinutuzumab vs Chlorambucil-Obinutuzumab To Treat CLL
Achieving undetectable MRD with ibrutinib plus venetoclax for CLL
